Are you ready to amplify your academic presence and connect with a global network of researchers? Join the Scholar Indexing Society and elevate your research to new heights!
Another Win for SGLT2 Inhibitors in Chronic Kidney Disease
Article Number: SIS479615AI220525
22nd May, 2025
Author(s):
David E. Leaf, M.D.; Nisha Bansal, M.D.
Abstract:
Chronic kidney disease (CKD) affects 14% of the U.S. population and poses substantial risks for end-stage kidney disease, cardiovascular events, and mortality. Despite therapeutic stagnation, sodium-glucose cotransporter 2 (SGLT2) inhibitors have transformed CKD treatment. The EMPA-KIDNEY trial demonstrated that empagliflozin (10 mg daily) significantly reduced disease progression and cardiovascular deaths (hazard ratio 0.72; 95% CI 0.64–0.82).
The EMPA-KIDNEY follow-up trial assessed empagliflozin's impact after discontinuation. Among 4891 participants, event rates nearly doubled compared to the active trial, providing robust data. Post-trial benefit persisted, though attenuated (hazard ratio 0.87; 95% CI 0.76–0.99), with early gains evident at six months (hazard ratio 0.60; 95% CI 0.38–0.93). Unlike the initial trial, post-trial findings revealed benefit even among patients with low urinary albumin-to-creatinine ratios.
The study highlights the carryover effects of SGLT2 inhibitors in CKD progression, with mechanisms potentially involving intraglomerular pressure reduction, sodium and glucose reabsorption modulation, and systemic adaptations. Future research should investigate long-term physiological benefits and optimal combination therapies